VCTC Expands to Spain with Appointment of Melissa VanKirk as Managing Director
VCTC Ltd., a multi-therapeutic, patient-centric clinical trial centre, is proud to announce its expansion into Spain, under the entity of VCTC Research SL, marking a major milestone in the company’s growth.
VCTC, which has built a strong reputation for conducting clinical trials in rare disease, neurology, reproductive health, infectious disease, and dermatology, will now offer its expert services in Spain, with new studies set to commence later this year.
VCTC’s expansion is part of a broader strategic initiative to enhance access to high-quality, patient-centric clinical research across Europe.
The new centre in Spain will mirror the company’s successful UK operations, which combine virtual, decentralised trial capabilities with traditional site-based models, allowing for flexible, cost-effective solutions for sponsors while improving patient access to clinical trials.
Alongside this expansion, VCTC is pleased to announce the appointment of Melissa VanKirk as Managing Director of VCTC Research SL. Melissa brings extensive experience in clinical operations, leadership, and innovation from her previous roles in global clinical research and will play a key role in driving VCTC’s vision for expanding its network across Europe.
"We are thrilled to enhance the clinical trial experience for participants in Spain and partner with Melissa VanKirk to lead this new chapter for VCTC," said Helen Shaw, Co-Founder of VCTC Ltd.
"Her proven leadership and commitment to advancing clinical research align perfectly with our goals of delivering innovative, patient-centric trials,” added Daniel Henley, Co-Founder and Managing Director of VCTC Ltd.
Melissa VanKirk stated, "I am honoured to be joining VCTC during such an exciting time of growth. I look forward to leading our team in Spain and building on the company’s commitment to making clinical research accessible and meaningful for anyone, anywhere."
VCTC’s expansion into Spain underscores its commitment to expanding its footprint in Europe while maintaining its high standards of care and operational excellence. The company will continue to work closely with its UK operations to ensure seamless integration and quality across all trial sites.
